BioMarin Expands Enzyme Therapies Portfolio with Inozyme Acquisition
BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire clinical-stage biotech Inozyme Pharma, Inc. for approximately $270 million
Read moreBioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire clinical-stage biotech Inozyme Pharma, Inc. for approximately $270 million
Read moreIn a strategic move to expand its oncology pipeline, GSK plc (LSE/NYSE: GSK) announced on Tuesday, it has entered into
Read moreGlobal biopharmaceutical leader AstraZeneca has officially opened a new $300 million state-of-the-art cell therapy manufacturing facility in Rockville, Maryland, marking
Read moreMerck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read moreIn a transformative move for the U.S. healthcare manufacturing sector, Roche unveiled plans to invest $50 billion in American pharmaceutical
Read moreEli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read moreLexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin therapy in development for
Read moreAs we approach the midpoint of the 2020s, the pharmaceutical industry has undergone a radical digital transformation, driven by the
Read moreNovartis has received its third U.S. Food and Drug Administration (FDA) approval for Fabhalta® (iptacopan), marking a major milestone as
Read moreIn a significant move to expand its oncology portfolio, Taiho Pharmaceutical Co., Ltd. has entered a definitive agreement to fully
Read more